Pharmacoeconomic Analysis of Acute Exacerbation of Chronic Obstructive Pulmonary Disease

Simple item page
dc.contributor.authorIqbal, Muhammad Shahiden_US
dc.contributor.authorFahad I. Al-Saikhanen_US
dc.contributor.authorAhmed, Nehad J.en_US
dc.contributor.authorIqbal, Muhammad Zahiden_US
dc.date.accessioned2020-11-18T10:30:22Z
dc.date.available2020-11-18T10:30:22Z
dc.date.issued2020-04
dc.description.abstractIntroduction:Chronic obstructive pulmonary disease (COPD) imparts a substantial economic burden on an individual and society. Exacerbation of COPD (ECOPD) is the primary cost driver for this burden as it usually associated with hospital admissions of COPD patients. The present study aimed to determine the direct costs of acute ECOPD among COPD patients.Methods:A total of 90 eligible patients with acute ECOPD who were admitted to the hospital were involved in this study. A convenient sampling technique was used during data collection. Cost data were collected according to the expenditures and existing information. Data were analyzed using Statistical Package for the Social Sciences (SPSS) version 23.0. TheSpearman's rank test was used to observe the differences (correlations) between the Govt perspective and the patient perspective.Results:The direct costs per episode of acute ECOPD were determined according to the Anthonisen criteria for evaluating acute ECOPD. The mean direct costs for severity III, severity I and severity I were 89.1, 134.8 and 178.2 USD respectively. The cost of acute ECOPD was positively associated with disease severity, length of hospital stay and the number of co-morbidities.Conclusion:Acute ECOPD patients consume a considerable amount of healthcare resources and pose a significant economic burden on the governmenten_US
dc.identifier.affiliationsDepartment of Clinical Pharmacy, College of Pharmacy, Prince Sattam Bin Abdulaziz University,Al-kharj, 11942, Saudi Arabiaen_US
dc.identifier.affiliationsDepartment of Clinical Pharmacy, College of Pharmacy, Prince Sattam Bin Abdulaziz University,Al-kharj, 11942, Saudi Arabiaen_US
dc.identifier.affiliationsDepartment of Clinical Pharmacy, College of Pharmacy, Prince Sattam Bin Abdulaziz University,Al-kharj, 11942, Saudi Arabiaen_US
dc.identifier.affiliationsDepartment of Clinical Pharmacy and Pharmacy Practice, Faculty of Pharmacy, AIMST University, 08100, Bedong, Kedah Darul Aman, Malaysia.en_US
dc.identifier.citationIqbal Muhammad Shahid, Fahad I. Al-Saikhan, Ahmed Nehad J., Iqbal Muhammad Zahid. Pharmacoeconomic Analysis of Acute Exacerbation of Chronic Obstructive Pulmonary Disease. Journal of Pharmaceutical Research International. 2020 Apr; 32(4): 59-66en_US
dc.identifier.issn2456-9119
dc.identifier.issn2231-2919
dc.identifier.placeIndiaen_US
dc.identifier.urihttps://imsear.searo.who.int/handle/123456789/215924
dc.languageenen_US
dc.publisherSCIENCEDOMAIN internationalen_US
dc.relation.issuenumber4en_US
dc.relation.volume32en_US
dc.source.urihttps://doi.org/10.9734/JPRI/2020/v32i430426en_US
dc.subjectCOPD;exacerbation;cost;pharmacoeconomics;acute ECOPDen_US
dc.titlePharmacoeconomic Analysis of Acute Exacerbation of Chronic Obstructive Pulmonary Diseaseen_US
dc.typeJournal Articleen_US
Files
Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
jpri2020v32n4p59.pdf
Size:
179.04 KB
Format:
Adobe Portable Document Format
Download
Collections
Journal of Pharmaceutical Research International